Safety and Efficacy of Ferula asafoetida in Functional Dyspepsia: A Randomized, Double-Blinded, Placebo-Controlled Study
Table 4
Statistical comparison of dyspepsia indexing scores.
Name of Tool
Intergroup comparison based on independent sample t-test
Inner group comparison based on paired sample t-test
95 CI Values
Mean difference comparison of variables using independent sample t-test
p-value
Time of Observation
Placebo
Asafin
Groups
Baseline
End of Study
GSRS
Baseline
45.33±0.77
43.91±0.76
Placebo
45.09±0.72
39.09±0.07
2.61
6.00±0.33
End of study
39.09±0.67
18.90±0.67#
Asafin
44.19±0.85
18.40±0.67#
54.98
25.28±0.89
GDSS
Baseline
10.79±0.20
10.45±0.21
Placebo
10.77±0.22
9.22±0.23
1.70
1.90±0.20
p<0.001
End of study
9.22±0.23
4.80±0.17
Asafin
10.47±0.22
4.80±0.17
28.02
5.66±0.24
NDI
Baseline
38.95±1.20
37.25±0.68
Placebo
39.09±1.28
33.77±1.07
2.06
5.38±0.46
End of study
33.77±1.07
20.71±1.09+
Asafin
37.28±0.71
20.71±1.09+
35.08
16.57±1.16
Statistical comparison of GSRS, Gastrointestinal Symptom Rating Scale; GDSS, Glasgow Dyspepsia Severity Score; and NDI, Nepean Dyspepsia Index values of Placebo with Asafin using paired sample t-test (within group) and independent sample t-test (between groups). The results are given as mean ± SEM. Values having a superscript significantly differ from its placebo at p<0.001. 95% CI values and mean difference comparison are also given.